Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 4, 2003

View Archived Issues

PH-027, a novel antimicrobial agent, has potent activity against anaerobic bacteria

NO blocks platelet-leukocyte aggregate formation in acute respiratory distress syndrome

Cathepsin B as a therapeutic target in cancer and arthritis

Duloxetine for painful diabetic neuropathy

Rapid absorption and onset of action for insulin glulisine in dogs and humans

Novel cathepsin K inhibitors in GSK development pipeline

ACAT inhibitors prepared and tested at Takeda

Yamanouchi scientists describe new PARP inhibitors and their use

Shionogi patent describes new antidiabetic agents

Novel group II mGluR antagonists under study at Taisho

Beneficial effects described for inhaled insulin in type 2 diabetes

Potential role for ruboxistaurin in diabetic microvascular complications

Acetyl-CoA carboxylase inhibitors, their preparation and use claimed by Ajinomoto

Neuroprotective effects of AT-1015 in rats with diabetic neuropathy

Mechanism of protective effects of pyridoxamine against diabetic nephropathy

Second approvable letter issued for duloxetine

TLK-286 awarded fast track status for advanced ovarian cancer

Avandia label expanded in Europe

New PPARalpha activator improves insulin sensitivity and lipid profiles in primates

HIM2 effects on glucose production and disposal in nondiabetic subjects

Rifaximin efficacy confirmed in phase III travelers' diarrhea trial

Satraplatin phase III trial cleared to begin

Paxil CR approved for premenstrual dysphoric disorder

BMS returns quinolone antibiotic to Toyama

Bifeprunox to enter phase III development for schizophrenia

FluMist available for 2003-2004 influenza season

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...